HER2 dual targeting with trastuzumab in combination with pertuzumab is nowadays the gold standard therapeutic approach for HER2+ breast cancer in the neoadjuvant setting and in the first-line treatment of metastatic disease. This evidence concerns the gene ERBB2 and metastatic neoplasm.